Jinxin Fertility Group Limited (abbrev. “JXR”) disclosed that it repurchased 1.14 million ordinary shares on the Hong Kong Exchange on 19 May 2026 at HKD 2.34–2.35 per share, spending HKD 2.67 million in aggregate. All repurchased shares are earmarked for cancellation.

Including this latest purchase, a total of 31.89 million shares bought between 27 March and 19 May 2026 remain pending cancellation. This represents approximately 1.18% of JXR’s current issued share base of 2.71 billion shares. Until cancellation is completed, the company’s issued share capital remains unchanged. JXR holds no treasury shares.

Under the shareholder mandate granted on 26 June 2025, the company may repurchase up to 274.47 million shares. After the latest transaction, 71.55 million shares—about 2.61% of the issued share count at the mandate date—have been repurchased, leaving an authorised balance of roughly 202.92 million shares.

The company is subject to a moratorium on issuing new shares or transferring any treasury shares until 18 June 2026, in line with Hong Kong Listing Rule 10.06(3)(a).